Merck drug Winrevair is the first in a new class of pulmonary arterial hypertension therapies that address a key signaling pathway behind the disease. The drug comes from Merck’s $11.5 billion acquisition of Acceleron Pharma.
Sanofi is acquiring Inhibrx to get its hands on a drug candidate in pivotal testing for the protein deficiency alpha-1 antitrypsin deficiency, which leads to lung and liver problems. Inhibrx’s remaining assets will be spun out into a new company.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Butterfly Network recently launched an AI tool that can provide medical practitioners with an accurate B-line count from just a six-second lung ultrasound clip. By automatically counting B-lines in a lung image, the tool helps doctors quickly identify and assess a patient's lung issues at the point of care.
ReCode Therapeutics closed an $80 million Series B round of financing that included Pfizer and Sanofi as investors. The startup’s technology uses lipid nanoparticles to deliver genetic medicines, and its two lead programs are for rare lung disorders.
A patient-first approach offers a proactive, process-driven program that leverages telehealth consults which can effectively mitigate the transmission of infection, such as coronavirus, for these vulnerable individuals.
California startup Rox Medical, which makes an implanted medical device to treat severe chronic obstructive pulmonary disease, has raised $5 million in search of $9 million.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
A Bristol-Myers Squibb (NYSE:BMY) lung disease drug candidate is moving ahead in clinical development under a new partnership with Duke University. Under the alliance, Bristol-Myers scientists will work with the Duke Translational Medicine Institute on phase 2 clinical development of BMS-986202, a compound being studied as a treatment for idiopathic pulmonary fibrosis or IPF. A […]
A study exploring lung repair and tissue regeneration to fight lung diseases by a team at the Perelman School of Medicine at the University of Pennsylvania in Philadelphia has received a $2.5 million grant. The grant was awarded by the National Heart, Lung, and Blood Institute’s Lung Repair and Regeneration Consortium to six institutions, including […]